Endogenous cannabinoid signaling

Neurobiology of Disease

Volumn 5, Issue 6, 1998, Pages 462-473

  Piomelli, Daniele ^a   Beltramo, Massimiliano ^a   Giuffrida, Andrea ^a   Stella, Nephi ^a  

^a NEUROSCIENCES INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ACYLTRANSFERASE; ANANDAMIDE; ARACHIDONIC ACID; CANNABINOID; CANNABINOID RECEPTOR; DIACYLGLYCEROL; LIPID BINDING PROTEIN; LIPOPROTEIN LIPASE; LYSOPHOSPHOLIPASE; PHOSPHODIESTERASE; PHOSPHOLIPASE A1; PHOSPHOLIPASE C; UNCLASSIFIED DRUG;

ARTICLE; BIOSYNTHESIS; CALCIUM CELL LEVEL; CELL MEMBRANE TRANSPORT; HUMAN; HYDROLYSIS; NEUROSECRETION; NEUROTRANSMISSION; NEUROTRANSMITTER RELEASE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

EID: 0032467803     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1006/nbdi.1998.0221     Document Type: Article

References (79)

1. Devane W. A., Dysarz F. A. III, Johnson M. R., Melvin L. S., Howlett A. C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 34:1988;605-613.
2. Matsuda L. A., Lolait S. J., Brownstein M., Young A., Bonner T. I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
3. Munro S., Thomas K. L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
4. Devane W. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
5. Sugiura T., Itoh K., Waku K., Hanahan D. J. Biological activities ofNN. Proc. Jpn. Conf. Biochem. Lipids. 36:1994;71-74.
6. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., Waku K. 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. 215:1995;89-97.
7. Mechoulam R. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. 50:1995;83-90.
8. Landsman R. S., Burkey T. H., Consroe P., Roeske W. R., Yamamura H. I. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. Eur. J. Pharmacol. 334:1997;R1-R2.
9. Piomelli D. Arachidonic acid in cell signalling. Curr. Opin. Cell Biol. 5:1993;274-280.
10. Piomelli D. Arachidonic Acid in Cell Signalling. 1996;R. G. Landes Co. Austin.
11. Devane W. A., Axelrod J. Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes. Proc. Natl. Acad. Sci. USA. 91:1994;6698-6701.
12. Kruszka K. K., Gross R. W. The ATP- and CoA-independent synthesis of arachidonoylethanolamide. J. Biol. Chem. 269:1994;14345-14348.
13. Ueda N., Kurahashi Y., Yamamoto S., Tokunaga T. Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. J. Biol. Chem. 270:1995;23823-23827.
14. Kurahashi Y., Ueda N., Suzuki H., Suzuki M., Yamamoto S. Reversible hydrolysis and synthesis of anandamide demonstrated by recombinant rat fatty-acid amide hydrolase. Biochem. Biophys. Res. Commun. 237:1997;512-515.
15. Deutsch D. G., Chin S. A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46:1993;791-796.
16. Fontana A., Di Marzo V., Cadas H., Piomelli D. Analysis of anandamide, an endogenous cannabinoid substance, and of other naturalN. Prostaglandins Leukotrienes Essent. Fatty Acid. 53:1995;301-308.
17. Nitsch R. M., Blusztajn J. K., Doyle F. M., Robitaille Y., Wurtman R. J., Growdon J. H., Kish S. J. Phospholipid metabolite levels are altered in cerebral cortex of patients with dominantly inherited olivopontocerebellar atrophy. Neurosci. Lett. 161:1993;191-194.
18. Shiao Y. J., Vance J. E. Evidence for an ethanolamine cycle: Differential recycling of the ethanolamine moiety of phosphatidylethanolamine derived from phosphatidylserine and ethanolamine. Biochem. J. 310:1995;673-679.
19. Schmid P. C., Paria B. C., Krebsbach R. J., Schmid H. H. O., Dey S. K. Changes in anandamide levels in mouse uterus are associated with uterine receptivity for embryo implantation. Proc. Natl. Acad. Sci. USA. 94:1997;4188-4192.
20. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.-C., Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 372:1994;686-691.
21. Cadas H., Gaillet S., Beltramo M., Venance L., Piomelli D. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J. Neurosci. 16:1996;3934-3942.
22. 2+. Biochem. Biophys. Res. Commun. 218:1996;113-117.
23. Sugiura T., Kondo S., Sukagawa A., Tonegawa T., Nakane S., Yamashita A., Ishima Y., Waku K. Transacylase-mediated and phosphodiesterase-mediated synthesis ofN. Eur. J. Biochem. 240:1996;53-62.
24. Cadas H., di Tomaso E., Piomelli D. Occurrence and biosynthesis of endogenous cannabinoid precursor,N. J. Neurosci. 17:1997;1226-1242.
25. Sasaki T., Chang M. C. J. NN. Life Sci. 61:1997;1803-1810.
26. Felder C. C., Briley E. M., Axelrod J., Simon J. T., Mackie K., Devane W. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci. USA. 90:1993;7656-7660.
27. Schmid H. H. O., Schmid P. C., Natarajan V. N-Acylated glycerophospholipids and their derivatives. Prog. Lipid Res. 29:1990;1-43.
28. Schmid H. H. O., Schmid P. C., Natarajan V. The N-acylation-phosphodiesterase pathway and cell signalling. Chem. Phys. Lipids. 80:1996;133-142.
29. Facci L., Dal Toso R., Romanello S., Buriani A., Skaper S. D., Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. USA. 92:1995;3376-3380.
30. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 394:1998;277-281.
31. Rinaldi-Carmona M. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther. 284:1998;644-650.
32. Showalter V. M., Compton D. R., Martin B. R., Abood M. E. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): Identification of cannabinoid receptor subtype selective ligands. J. Pharmacol. Exp. Ther. 278:1996;989-999.
33. Ross, R. A. Templeton, F. Green, A. Pertwee, R. G. 1998, L759633, L759656 and palmitoylethanolamide: Are they CB2-selective agonists, International Cannabinoid Research Society.
34. Chapman K. D., Conyers-Jackson A., Moreau R. A., Tripathy S. IncreasedN. Physiol. Plant. 95:1995;120-126.
35. Chapman K. D., Tripathy S., Venables B., Desouza A. D. N. Plant Physiol. 116:1998;1163-1168.
36. Cabot M. C., Gatt S. Hydrolysis of endogenous diacylglycerol and monoacylglycerol by lipases in rat brain microsomes. Biochemistry. 16:1977;2330-2334.
37. Bell R. L., Kennerly D. A., Stanford N., Majerus P. W. Diglyceride lipase: A pathway for arachidonate release from human platelets. Proc. Natl. Acad. Sci. USA. 76:1979;3238-3241.
38. Farooqui A. A., Taylor W. A., Horrocks L. A. Characterization and solubilization of membrane bound diacylglycerol lipases from bovine brain. Int. J. Biochem. 18:1986;991-997.
39. Farooqui A. A., Anderson D. K., Horrocks L. A. Effect of glutamate and its analogue on diacylglycerol and monoacylglycerol lipase activities on neuron-enriched cultures. Brain Res. 604:1993;180-184.
40. 2. Curr. Opin. Cell Biol. 7:1995;183-189.
41. Exton J. H. Regulation of phosphoinositide phospholipases by hormones, neurotransmitters, and other agonists linked to G proteins. Annu. Rev. Pharmacol. Toxicol. 36:1996;481-509.
42. Brindley D. N. Biochemistry of Lipids and Membranes. 1985;Benjamin/Cummings, Menlo Park. p. 213-241.
43. Stella N., Schweitzer P., Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature. 388:1997;773-778.
44. Yue T. L., Feuerstein G. Z. Platelet-activating factor: A putative neuromodulator and mediator in the pathophysiology of brain injury. Crit. Rev. Neurobiol. 8:1994;11-24.
45. Herkenham M., Lynn A. B., Little M. D., Johnson M. R., Melvin L. S., de Costa B. R., Rice K. C. Cannabinoid receptor localization in brain. Proc. Natl. Acad. Sci. USA. 87:1990;1932-1936.
46. Tsou K., Brown S., Sañudo-Peña M. C., Mackie K., Walker J. M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 83:1998;393-411.
47. Schmid P. C., Krebsbach R. J., Perry S. R., Dettmer T. M., Maasson J. L., Schmid H. H. O. Occurrence and postmortem generation of anandamide and other long-chainN. FEBS Lett. 375:1995;177-120.
48. Felder C. C. Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. FEBS Lett. 393:1996;231-235.
49. Smith J. E., Lane J. D., Shea P. A., McBride W. J., Aprison M. H. A method for concurrent measurement of picomole quantities of acetylcholine, choline, dopamine, norepinephrine, serotonine, 5-hydroxytryptophan, 5-hydroxyindoleacetic acid, tryptophan, tyrosine, glycine, asparatate, glutamate, alanine, and γ-aminobutyric acid in single tissue samples from different areas of rat central nervous system. Anal. Biochem. 64:1975;149-169.
50. Giuffrida, A. Parsons, L. H. Kerr, T. H. Rodríguez de Fonseca, F. Navarro, M. Piomelli, D. Dopamine activation of endogenous cannabinoid signalling in dorsal striatum.
51. Venance L., Piomelli D., Glowinski J., Giaume C. Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature. 376:1995;590-594.
52. Cadas H., Schinelli S., Piomelli D. Membrane localization ofN. J. Lipid Mediators Cell Signalling. 14:1996;63-70.
53. Hecht J. H., Weiner J. A., Post S. R., Chun J. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J. Cell. Biol. 135:1996;1071-1083.
54. Stein W. D. Channels and Pumps. An Introduction to Membrane Transport. 1990;Academic Press, San Diego.
55. Beltramo M., Stella N., Calignano A., Lin S. Y., Makriyannis A., Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 277:1997;1094-1097.
56. Hillard C. J., Edgemond W. S., Jarrahian A., Campbell W. B. Accumulation ofN. J. Neurochem. 69:1997;631-638.
57. Calignano A., LaRana G., Beltramo M., Makriyannis A., Piomelli D. Potentiation of anandamide hypotension by the transport inhibitor, AM404. Eur. J. Pharmacol. 337:1997;R1-R2.
58. Kanai N., Lu R., Satriano J. A., Bao Y., Wolkoff A. W., Schuster V. L. Identification and characterization of a prostaglandin transporter. Science. 268:1995;866-869.
59. Schuster V. L. Molecular mechanisms of prostaglandin transport. Annu. Rev. Physiol. 60:1998;221-242.
60. Desarnaud F., Cadas H., Piomelli D. Anandamide amidohydrolase activity in rat brain microsomes: Identification and partial characterization. J. Biol. Chem. 270:1995;6030-6035.
61. Hillard C. J., Wilkison D. M., Edgemond W. S., Campbell W. B. Characterization of the kinetics and distribution ofN. Bba-Lipid Lipid Metab. 1257:1995;249-256.
62. Cravatt B. F., Giang D. K., Mayfield S. P., Boger D. L., Lerner R. A., Gilula N. B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 384:1996;83-87.
63. Koutek B., Prestwich G. D., Howlett A. C., Chin S. A., Salehani D., Akhavan N., Deutsch D. G. Inhibitors of arachidonoyl ethanolamide hydrolysis. J. Biol. Chem. 269:1994;22937-22940.
64. Lang W. S., Qin C., Hill W. A. G., Lin S. Y., Khanolkar A. D., Makriyannis A. High-performance liquid chromatographic determination of anandamide amidase activity in rat brain microsomes. Anal. Biochem. 238:1996;40-45.
65. Beltramo M., di Tomaso E., Piomelli D. Inhibition of anandamide hydrolysis in rat brain tissue by (EH. FEBS Lett. 403:1997;263-267.
66. Schäffer J. E., Lodish H. F. Expression cloning and characterization of a novel adipocyte long chain fatty acid transporter protein. Cell. 79:1994;427-436.
67. Baldessarini R. J. The Pharmacological Basis of Therapeutics. 1990;Pergamon Press, New York. p. 383-435.
68. Tang W., Bunting M., Zimmerman G. A., McIntyre T. M., Prescott S. M. Molecular cloning of a novel human diacylglycerol kinase highly selective for arachidonate-containing substrate. J. Biol. Chem. 271:1996;10237-10241.
69. Varga K., Wagner J. A., Bridgen T., Kunos G. Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension. FASEB J. 12:1998;1035-1044.
70. Richardson J. D., Aanonsen L., Hargreaves K. M. SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice. Eur. J. Pharmacol. 319:1997;R3-R4.
71. Richardson J. D., Aanonsen L., Hargreaves K. M. Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia. J. Neurosci. 18:1998;451-457.
72. Santucci V., Storme J. J., Soubrié P., Lefur G. Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist sr 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis. Life Sci. 58:1996;PL103-PL110.
73. Terranova J. P., Storme J. J., Lafon N., Perio A., Rinaldicarmona M., Lefur G., Soubrie P. Improvement of memory in rodents by the selective CB1 cannabinoid receptor antagonist, SR 141716. Psychopharmacology. 126:1996;165-172.
74. Navarro M., Hernández E., Munoz R. M., del Arco I., Villanúa M. A., Carrera M. R., Rodríguez de Fonseca F. Acute administration of the CB1 cannabinoid receptor antagonist SR141716A induces anxiety-like responses in the rat. NeuroReport. 8:1997;491-496.
75. Gifford A. N., Ashby C. R. Electrically evoked acetylcholine release from hippocampal slices is inhibited by the cannabinoid receptor agonist, WIN 55212-2, and is potentiated by the cannabinoid antagonist, SR 141716A. J. Pharmacol. Exp. Ther. 277:1996;1431-1436.
76. Gessa G.-L., Melis M., Muntoni A.-L., Diana M. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur. J. Pharmacol. 340:1998;R7-R8.
77. Akoka S., Tellier C., Le Roux C., Marion D. A phosphorus magnetic resonance spectroscopy and a differential scanning calorimetry study of the physical properties ofN. Chem. Phys. Lipids. 46:1988;43-50.
78. Blank M. L., Cress E. A., Robinson M., Snyder F. Metabolism of unique diarachidonoyl and linoleoylarachidonoyl species of ethanolamine and choline phosphoglycerides in rat testes. Biochem. Biophys. Acta. 833:1985;366-371.
79. Chilton F. H., Murphy R. C. Stimulated production and natural occurrence of 1,2-diarachidonoylglycerophosphocholine in human neutrophils. Biochem. Biophys. Res. Commun. 145:1987;1126-1133.